Novel method of stabilizing diagnostic and therapeutic compounds in a cationic carrier system

Details for Australian Patent Application No. 2003249882 (hide)

Owner MediGene AG

Inventors Peymann, Toralf; Fichert, Thomas; Michaelis, Uwe; Schulze, Brita; Teifel, Michael; Haas, Heinrich

Agent Davies Collison Cave

Pub. Number AU-B-2003249882

PCT Number PCT/EP03/06765

PCT Pub. Number WO2004/002455

Priority 60/391,246 26.06.02 US; 03 004 744.3 04.03.03 EP; 02 018 724.1 21.08.02 EP; 60/391,245 26.06.02 US; 60/391,244 26.06.02 US; 02 018 907.2 23.08.02 EP

Filing date 26 June 2003

Wipo publication date 19 January 2004

Acceptance publication date 18 September 2008

International Classifications

A61K 47/18 (2006.01) Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives

A61K 9/127 (2006.01) Medicinal preparations characterised by special physical form - Liposomes

A61K 31/00 (2006.01)

A61K 31/335 (2006.01) - having oxygen as the only ring hetero atom, e.g. fungichromin

A61K 31/337 (2006.01) - having four-membered rings, e.g. taxol

A61K 31/47 (2006.01) - Quinolines

A61K 31/4745 (2006.01)

A61K 47/24 (2006.01) Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives - containing atoms other than carbon, hydrogen, halogen, oxygen, nitrogen or sulfur

A61K 47/28 (2006.01) Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives - Steroids

A61K 47/34 (2006.01) Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds

A61K 47/48 (2006.01) Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives - the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates

A61K 49/00 (2006.01) Preparations for testing

A61K 49/18 (2006.01) Preparations for testing

A61P 9/00 (2006.01) Drugs for disorders of the cardiovascular system

A61P 11/06 (2006.01) Drugs for disorders of the respiratory system

A61P 17/02 (2006.01) Drugs for dermatological disorders

A61P 19/02 (2006.01) Drugs for skeletal disorders

A61P 27/02 (2006.01) Drugs for disorders of the senses

A61P 29/00 (2006.01) Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents

A61P 35/00 (2006.01) Antineoplastic agents

A61P 43/00 (2006.01) Drugs for specific purposes, not provided for in groups

Event Publications

16 October 2003 Complete Application Filed

  Priority application(s): 60/391,246 26.06.02 US; 03 004 744.3 04.03.03 EP; 02 018 724.1 21.08.02 EP; 60/391,245 26.06.02 US; 60/391,244 26.06.02 US; 02 018 907.2 23.08.02 EP

4 March 2004 Application Open to Public Inspection

  Published as AU-B-2003249882

28 April 2005 Amendment Made

  The nature of the amendment is as shown in the statement(s) filed 28 Jan 2005

5 October 2006 Assignment before Grant

  MediGene Oncology GmbH The application has been assigned to MediGene AG

18 September 2008 Application Accepted

  Published as AU-B-2003249882

22 January 2009 Standard Patent Sealed

27 January 2011 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This patent ceased under section 143(a), or Expired. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2003249883-SECRETED POLYPEPTIDE SPECIES ASSOCIATED WITH CARDIOVASCULAR DISORDERS

2003249881-DIARYLMETHYLPIPERAZINES AS PROPHYLACTIC OR THERAPEUTIC AGENTS FOR VIRAL MYOCARDITIS